Who are the children at risk? Lessons learned from measles outbreaks

Epidemiology and Infection

Volumn 140, Issue 9, 2012, Pages 1578-1588

  Stein Zamir, C ^a   Shoob, H ^a   Abramson, N ^a   Zentner, G ^a  

^a MINISTRY OF HEALTH   (Israel)

Author keywords

Children's vaccines; measles (rubeola); outbreaks; vaccination (immunization)

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE;

ARTICLE; EPIDEMIC; EPIDEMIOLOGICAL DATA; HEALTH CARE; HUMAN; INFECTION RISK; ISRAEL; LABORATORY TEST; MEASLES; MEASLES VACCINATION; MORBIDITY; PATIENT COMPLIANCE; QUESTIONNAIRE; REGISTRATION; SEROLOGY;

ADOLESCENT; ADULT; AGE FACTORS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; DISEASE OUTBREAKS; FEMALE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; ISRAEL; MALE; MEASLES; MEASLES-MUMPS-RUBELLA VACCINE; MIDDLE AGED; RISK FACTORS; YOUNG ADULT;

EID: 84864472562     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S095026881100238X     Document Type: Article

References (41)

1. Centers for Disease Control and Prevention. Progress in global measles control and mortality reduction, 2000-2006. Morbidity and Mortality Weekly Report 2007; 56: 1237-1241.
2. Centers for Disease Control and Prevention. Progress toward measles mortality reduction and elimination-Eastern Mediterranean Region, 1997-2007. Morbidity and Mortality Weekly Report 2008; 57: 262-267.
3. Muller CP, et al. WHO Steering Committee for Measles and Rubella. Reducing global disease burden of measles and rubella: report of the WHO Steering Committee on research related to measles and rubella vaccines and vaccination, 2005. Vaccine 2007; 25: 1-9. (Pubitemid 44855256)
4. Wichmann O, et al. Large measles outbreak at a German public school, 2006. Pediatric Infectious Disease Journal 2007; 26: 82-86.
5. Parker AA, et al. Implications of a 2005 measles outbreak in Indiana for sustained elimination of measles in the United States. New England Journal of Medicine 2006; 355: 447-455. (Pubitemid 44162272)
6. Parker Fiebelkorn A, et al. Measles in the United States during the post-elimination era. Journal of Infectious Diseases 2010; 202: 1520-1528.
7. Muscat M, Bang H, Glismann S. Measles is still a cause for concern in Europe. Eurosurveillance 2008; 13: pii=18837.
8. Andrews N, et al. Towards elimination: measles susceptibility in Australia and 17 European countries. Bulletin of the World Health Organization 2008; 86: 197-204. (Pubitemid 351480939)
9. Wichmann O, et al. Further efforts needed to achieve measles elimination in Germany: results of an outbreak investigation. Bulletin of the World Health Organization 2009; 87: 108-115.
10. Muscat M, et al. EUVAC.NET Group. Measles in Europe: an epidemiological assessment. Lancet 2009; 373: 383-389.
11. Kremer JR, Muller CP. Measles in Europe-there is room for improvement. Lancet 2009; 373: 356-358.
12. Meissner HC, Strebel PM, Orenstein WA. Measles vaccines and the potential for worldwide eradication of measles. Pediatrics 2004; 114: 1065-1069. (Pubitemid 41529774)
13. Obaro SK, Palmer A. Vaccines for children: policies, politics and poverty. Vaccine 2003; 21: 1423-1431. (Pubitemid 36263184)
14. Slater PE, Anis E, Leventhal A. Measles control in Israel: a decade of the two-dose policy. Public Health Review 1999; 27: 235-241. (Pubitemid 30353196)
15. Belmaker I, et al. Two-dose measles immunization as a strategy to eliminate measles in the Middle East and Israel. Israel Medical Association Journal 2008; 10: 640-645.
16. WHO. Monitoring and assessing immunization systems and safety. Immunization coverage. WHO, 2007 (www.who.int/immunization-monitoring/routine/ en/). Accessed 31 January 2011.
17. Stein-Zamir C, et al. Measles outbreaks affecting children in Jewish ultra-orthodox communities in Jerusalem. Epidemiology and Infection 2008; 136: 207-214.
18. Stewart-Freedman B, Kovalsky N. An ongoing outbreak of measles linked to the United Kingdom in an ultra-orthodox Jewish community in Israel. Eurosurveillance 2007; 12: E070920.1.
19. Stein-Zamir C, et al. An outbreak of measles in an ultra-orthodox Jewish community in Jerusalem, Israel, 2007-an in-depth report. Eurosurveillance 2008; 13(8): pii=8045.
20. Anis E, et al. Measles in a highly vaccinated society: the 2007-2008 outbreak in Israel. Journal of Infection 2009; 59: 252-258.
21. Centers for Disease Control and Prevention. Case definitions for infectious conditions under public health surveillance. Morbidity and Mortality Weekly Report. Recommendations and Reports 1997; 46(RR-10).
22. Central Bureau of Statistics. Israel-population by district, sub-district and religion 1948-2007. In: Statistical Abstract of Israel, No. 59. Jerusalem, 2008; Table 2.6, p. 98.
23. Central Bureau of Statistics. Israel: population, by population group, religion, age and sex, district and sub-district, 2007. In: Statistical Abstract of Israel, No. 59. Jerusalem, 2008: Table 2.10, p. 114.
24. SPSS Inc. Statistical Package for the Social Sciences (SPSS), version 14.0 for Windows, Chicago, SPSS Inc., 2005.
25. Abramson JH. WINPEPI (PEPI-for-Windows): computer programs for epidemiologist. Epidemiologic Perspectives and Innovations 2004; 1: 6.
26. de Quadros CA, et al. Feasibility of global measles eradication after interruption of transmission in the Americas. Expert Review of Vaccines 2008; 7: 355-362. (Pubitemid 351520023)
27. Israel Ministry of Health. Israel Center for Disease Control, Ministry of Health, Israel. Notifiable infectious diseases in Israel-54 years of surveillance. Jerusalem, 2006, Publication No. 245.
28. Dagan R, et al. Decay of maternally derived measles antibody in a highly vaccinated population in southern Israel. Pediatric Infectious Disease Journal 1995; 14: 965-969.
29. Leuridan E, et al. Early waning of maternal measles antibodies in era of measles elimination: longitudinal study. British Medical Journal 2010; 340: c1626.
30. Gagneur A, et al. Kinetics of decline of maternal measles virus-neutralizing antibodies in sera of infants in France in 2006. Clinical and Vaccine Immunology 2008; 15: 1845-1850.
31. Johansen K, Lopalco PL. Passive immunity against measles in infants: is there a need for policy changes in the European vaccination schedules? Eurosurveillance 2007; 12: E9-E10.
32. Metcalf CJ, et al. Modelling the first dose of measles vaccination: the role of maternal immunity, demographic factors, and delivery systems. Epidemiology and Infection 2011; 139: 265-274.
33. Leuridan E, Van Damme P. Passive transmission and persistence of naturally acquired or vaccine-induced maternal antibodies against measles in newborns. Vaccine 2007; 25: 6296-6304. (Pubitemid 47090234)
34. Stein-Zamir C, et al. The Israel National Immunization Registry. Israel Medical Association Journal 2010; 12: 296-300.
35. Guyer B, et al. Immunization coverage and its relationship to preventive health care visits among inner-city children in Baltimore. Pediatrics 1994; 94
36. Feemster KA, et al. Identifying infants at increased risk for late initiation of immunizations: maternal and provider characteristics. Public Health Reports 2009; 124: 42-53.
37. Poethko-Muller C, et al. Vaccination coverage against measles in German-born and foreign-born children and identification of unvaccinated subgroups in Germany. Vaccine 2009; 27: 2563-2569.
38. Jeong YW, et al. Timeliness of MMR vaccination and barriers to vaccination in preschool children. Epidemiology and Infection 2011; 139: 247-256.
39. Henderson L, Millett C, Thorogood N. Perceptions of childhood immunization in a minority community: qualitative study. Journal of the Royal Society of Medicine 2008; 101: 244-251. (Pubitemid 351860056)
40. Smailbegovic MS, Laing GJ, Bedford H. Why do parents decide against immunization? The effect of health beliefs and health professionals. Child: Care, Health and Development 2003; 29: 303-311. (Pubitemid 36833844)
41. Kennedy AM, Gust DA. Measles outbreak associated with a church congregation: a study of immunization attitudes of congregation members. Public Health Reports 2008; 123: 126-134.